4.3 Article

Establishment of a novel patient-derived Ewing's sarcoma cell line, NCC-ES1-C1

Journal

IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL
Volume 54, Issue 10, Pages 770-778

Publisher

SPRINGER
DOI: 10.1007/s11626-018-0302-2

Keywords

Ewing's sarcoma; EWSR1-FLI1; Cell line; Drug sensitivity

Funding

  1. National Cancer Center Research and Development Fund [26-A-3, 26-A-9, 29-A-2]
  2. Fundamental Innovative Oncology Core in the National Cancer Center

Ask authors/readers for more resources

Ewing's sarcoma is an aggressive mesenchymal tumor characterized by the presence of a unique EWSR1-FLI1 translocation. Ewing's sarcoma primarily occurs in the bone and soft tissues. Cell lines enable researchers to investigate the molecular backgrounds of disease and the significance of genetic alterations in relevant cellular contexts. Here, we report the establishment and characterization of a novel Ewing's sarcoma cell line following primary Ewing's sarcoma tumor tissue culture. The established cell line was authenticated by DNA microsatellite short tandem repeat analysis, characterized by in vitro assays, and named NCC-ES1-C1. The NCC-ES1-C1 cell line grew well for 15mo and was subcultured more than 50 times during this period. Characterization of the cells revealed that they were not adherent and showed floating features. In conclusion, we successfully established a novel Ewing's sarcoma cell line, NCC-ES1-C1, from primary tumor tissue. The cell line has the characteristic EWSR1-FLI1 gene fusion and exhibits aggressive growth in vitro. Thus, the NCC-ES1-C1 cell line will be a useful tool for investigating the mechanisms of disease and the biological role of the EWSR1-FLI1 fusion gene.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available